Thc Therapeutics Stock Performance
| THCT Stock | USD 0.0001 0.00 0.00% |
THC Therapeutics holds a performance score of 7 on a scale of zero to a hundred. The entity owns a Beta (Systematic Risk) of 8.46, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, THC Therapeutics will likely underperform. Use THC Therapeutics coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and day typical price , to analyze future returns on THC Therapeutics.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in THC Therapeutics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively inconsistent fundamental indicators, THC Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
THC |
THC Therapeutics Relative Risk vs. Return Landscape
If you would invest 0.01 in THC Therapeutics on October 28, 2025 and sell it today you would earn a total of 0.00 from holding THC Therapeutics or generate 0.0% return on investment over 90 days. THC Therapeutics is currently generating 3.9683% in daily expected returns and assumes 41.4472% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than THC, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
THC Therapeutics Target Price Odds to finish over Current Price
The tendency of THC Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.0001 | 90 days | 0.0001 | about 72.02 |
Based on a normal probability distribution, the odds of THC Therapeutics to move above the current price in 90 days from now is about 72.02 (This THC Therapeutics probability density function shows the probability of THC Pink Sheet to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the pink sheet has the beta coefficient of 8.46 . This usually implies as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, THC Therapeutics will likely underperform. In addition to that THC Therapeutics has an alpha of 3.1994, implying that it can generate a 3.2 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). THC Therapeutics Price Density |
| Price |
Predictive Modules for THC Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as THC Therapeutics. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of THC Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
THC Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. THC Therapeutics is not an exception. The market had few large corrections towards the THC Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold THC Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of THC Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 3.20 | |
β | Beta against Dow Jones | 8.46 | |
σ | Overall volatility | 0.000072 | |
Ir | Information ratio | 0.09 |
THC Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of THC Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for THC Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| THC Therapeutics is way too risky over 90 days horizon | |
| THC Therapeutics has some characteristics of a very speculative penny stock | |
| THC Therapeutics appears to be risky and price may revert if volatility continues | |
| THC Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| THC Therapeutics currently holds 925.89 K in liabilities with Debt to Equity (D/E) ratio of 18.7, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. THC Therapeutics has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist THC Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, THC Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like THC Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for THC to invest in growth at high rates of return. When we think about THC Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (1.89 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| THC Therapeutics currently holds about 3.82 K in cash with (388.48 K) of positive cash flow from operations. | |
| Roughly 31.0% of THC Therapeutics outstanding shares are owned by corporate insiders |
THC Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of THC Pink Sheet often depends not only on the future outlook of the current and potential THC Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. THC Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 16.6 M | |
| Cash And Short Term Investments | 296.1 K |
THC Therapeutics Fundamentals Growth
THC Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of THC Therapeutics, and THC Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on THC Pink Sheet performance.
| Return On Asset | -5.57 | |||
| Current Valuation | 1.57 M | |||
| Shares Outstanding | 34.15 M | |||
| Price To Earning | 1.25 X | |||
| Price To Book | 46.07 X | |||
| EBITDA | (1.06 M) | |||
| Cash And Equivalents | 3.82 K | |||
| Total Debt | 925.89 K | |||
| Debt To Equity | 18.70 % | |||
| Book Value Per Share | (0.15) X | |||
| Cash Flow From Operations | (388.48 K) | |||
| Earnings Per Share | (0.09) X | |||
| Total Asset | 480.07 K | |||
About THC Therapeutics Performance
Assessing THC Therapeutics' fundamental ratios provides investors with valuable insights into THC Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the THC Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
It is involved in the development of dHydronator, a sanitizing herb dryer for drying and sanitizing of freshly harvested cannabis, other herbs, flowers, and tea leaves. THC Therapeutics, Inc. was incorporated in 2007 and is based in Las Vegas, Nevada. Thc Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 1 people.Things to note about THC Therapeutics performance evaluation
Checking the ongoing alerts about THC Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for THC Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| THC Therapeutics is way too risky over 90 days horizon | |
| THC Therapeutics has some characteristics of a very speculative penny stock | |
| THC Therapeutics appears to be risky and price may revert if volatility continues | |
| THC Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| THC Therapeutics currently holds 925.89 K in liabilities with Debt to Equity (D/E) ratio of 18.7, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. THC Therapeutics has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist THC Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, THC Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like THC Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for THC to invest in growth at high rates of return. When we think about THC Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (1.89 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| THC Therapeutics currently holds about 3.82 K in cash with (388.48 K) of positive cash flow from operations. | |
| Roughly 31.0% of THC Therapeutics outstanding shares are owned by corporate insiders |
- Analyzing THC Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether THC Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining THC Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating THC Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of THC Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of THC Therapeutics' pink sheet. These opinions can provide insight into THC Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for THC Pink Sheet Analysis
When running THC Therapeutics' price analysis, check to measure THC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy THC Therapeutics is operating at the current time. Most of THC Therapeutics' value examination focuses on studying past and present price action to predict the probability of THC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move THC Therapeutics' price. Additionally, you may evaluate how the addition of THC Therapeutics to your portfolios can decrease your overall portfolio volatility.